| | |
| Clinical data | |
|---|---|
| Other names | 4-Methyl-THPI; 4-Me-THPI |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C14H16N2 |
| Molar mass | 212.296 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RS134-49, also known as 4-methyl-THPI, is a tetrahydropyridinylindole (THPI) derivative related to psychedelic tryptamines which acts as a 5-HT2A receptor agonist, with a 5-HT2A Ki of 11.5nM and an EC50 of 22nM. It is a biased agonist selective for activation of the Gq coupled signalling pathway with weaker activation of the β-arrestin 2 coupled pathway, but shows a more balanced profile than related compounds such as (R)-69. [1] [2]